QBL EGM, page-232

Hi Kate.
First of all let me state that I am certainly no expert in this venture capital field. My experiences over the years developed as a result of ‘getting into bed’ with a bunch of people who represented numerous start up companies ranging from computer software to biotech and everything in-between.
You state….’one thing I question in this comment being a venture capitalist investor that I am aware that in VC an exit strategy is usually always an imperative part of even considering a VC investment.’
And of course this is true however whilst I wholeheartedly agree with those words I am also of the opinion that no matter how much DD or research is completed before committing funds to a particular start-up it doesn’t necessarily follow that the path to listing or buy out thus triggering an exit WILL occur.
VC investing enabled me to develop a risk strategy which then allowed me to put my head on the pillow at night in the knowledge that my hard earned could possibly return me some serious coin with also the distinct possibility that it may return absolutely zippo.
The skeletons of some of those ‘zippo’ companies are sitting in the draw BELOW the bottom drawer of my filing cabinet.
As far as QBL/MCL is concerned I am reasonably confident particular in the MM path that they have taken that a reasonable, and it could be substantial ROI may occur.
One reason, and there are many others, for this line of thinking is due to the fact that I have a very close relation who is a drug Doctor Specialist. He attends conferences around the globe and has seen firsthand the benefits of MM in relation to treating the high end of drug affected patients. These results are now being documented on a daily basis. So it is not surprising that he was very supportive of it and in fact had just written up his first report backing the prescribing of MM for a patient.
There is no need to go into what appears at this stage to be the wonderful benefits of prescribing MM in the helping of the millions of sufferers of MS, epilepsy, Parkinson’s disease etc etc.
So the question specifically related to the global MM market is, can QBL/MCL get a sizeable piece of the investment action?
I'm confident, at least at this stage of proceedings that they will.
Time will tell.